Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?

Caitlin M. Gibson, Shannon W. Finks

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Edoxaban is the most recently approved factor Xa inhibitor within the class of direct oral anticoagulants (DOACs). Like other DOACs, edoxaban was approved by the US Food and Drug Administration for treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Similar to other DOACs, edoxaban has fewer drug–drug interactions than warfarin and does not require routine laboratory monitoring. Unlike other DOACs, edoxaban has yet to be approved for secondary or postoperative venous thromboembolism thromboprophylaxis. Currently no antidote for edoxaban is available. To optimally prescribe agents in the DOAC class, it is critical that providers 1) understand how the agents compare; and 2) identify specific settings in which one agent may be preferred over another.

Original languageEnglish
Pages (from-to)900-906
Number of pages7
JournalAmerican Journal of Medicine
Issue number8
StatePublished - Aug 2017


  • Anticoagulation
  • Atrial fibrillation
  • Direct oral anticoagulant
  • Edoxaban
  • Factor Xa inhibitors
  • Venous thromboembolism


Dive into the research topics of 'Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?'. Together they form a unique fingerprint.

Cite this